FDA approves epidiolex for epilepsy
Rajalaxmi Natarajan, PhD
The Food and Drug Administration (FDA) has approved epidiolex, made of cannabidiol (CBD) and derived from marijuana plant to treat Dravet Syndrome and Lennox-Gestaut Syndrome, rare childhood-onset forms of epilepsy. Epidiolex, marketed by GW Pharmaceuticals Plc is the first cannabis-based drug to receive FDA approval. This decision could encourage more research into the medicinal properties of cannabis to treat other epileptic conditions.